Histogenics Corporation (NASDAQ:HSGX) released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.07, Bloomberg Earnings reports.
Histogenics Corporation (NASDAQ HSGX) opened at $1.91 on Monday. Histogenics Corporation has a twelve month low of $1.45 and a twelve month high of $2.40.
HSGX has been the subject of a number of research reports. Zacks Investment Research lowered Histogenics Corporation from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. HC Wainwright restated a “buy” rating and issued a $3.50 price target on shares of Histogenics Corporation in a research report on Thursday, November 2nd. ValuEngine cut Histogenics Corporation from a “sell” rating to a “strong sell” rating in a report on Monday, August 14th. Finally, Canaccord Genuity restated a “buy” rating and set a $4.00 price target on shares of Histogenics Corporation in a research note on Friday, August 11th.
Histogenics Corporation Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.